Assessment of practice and perceptions of healthcare professionals regarding the contribution of inappropriate pharmaceutical compounding to adverse drug events (ADEs) and antimicrobial resistance (AMR)-Reference-Cited by-同舟云学术

Assessment of practice and perceptions of healthcare professionals regarding the contribution of inappropriate pharmaceutical compounding to adverse drug events (ADEs) and antimicrobial resistance (AMR)

Published:2024-08-16 Issue:1 Volume:3 Page:
ISSN:2731-7501
Container-title:Discover Health Systems
language:en
Short-container-title:Discov Health Systems

Author:

Ayenew Wondim,Bitew Teshome,Mohammed Abdulwase,Mengesha Assefa kebad,Chanie Gashaw Sisay,Mitku Melese Legesse,Melese Mihret,Gela Yibeltal Yismaw,Beyna Alemante Tafese,Esubalew Dereje,Simegn Wudneh,Limenh Liknaw Workie

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s44250-024-00133-2.pdf

Reference39 articles.

1. Galson SK. Federal and state role in pharmacy compounding and reconstitution: exploring the right mix to protect patients. Hearing on oversight before the senate comm. on health, education, labor, & pensions, 108th Cong. 2003. http://www.fda.gov/NewsEvents/Testimony/ucm115010.htm.

2. Yuliani SH, Putri DCA, Virginia DMSH, Gani MR, Riswanto FDO. Prevalence, risk, and challenges of extemporaneous preparation for pediatric patients in developing nations: a review. Pharmaceutics. 2023;15:840. https://doi.org/10.3390/pharmaceutics15030840.

3. U.S. Food & Drug Administration. FDA alerts health care professionals and compounders of potential risks associated with the compounding of remdesivir drug products. Updated 02/04/2021

4. Smith A, Jones JK, Wu S. Compounded medications: a systematic review. J Pharm Sci. 2020;109(7):2211–26.

5. Lee H, Woodcock J, Mazer-Amirshahi M, et al. US food and drug administration approval of flibanserin: even the score does not add up. JAMA Intern Med. 2019;179(10):1402–3.